Oxytocin is a female reproductive hormone which is secreted in hypothalamus and is released into the bloodstream during a childbirth to induce a labor and milk production in the lactating mother. Oxytocic drugs as a medication, can be used as an uterotonic i.e. as an agent to induce uterine contractions (induced labor) and to reduce hemorrhage after C-section. Besides, oxytocic drugs are also given in conditions such as uterine atony, post-mature birth, pre-eclampsia (hypertension in pregnancy), postpartum hemorrhage, stillbirth (death of baby in uterus), as an adjunct therapy in case of incomplete abortion and treatment of autism. Oxytocic drugs are also used in veterinary medicine. Endogenously secreted oxytocin manifests its effects towards the end of pregnancy, during child birth and just after delivery. Synthetic oxytocic drugs are devoid of antidiuretic activity due to absence of vasopressin. According to World Health Organization’s (WHO) preterm birth fact sheet 2015, each year 15 Mn babies are born prematurely across the globe and the number is on rise. As per National Center for Health Statistics, U.S. reported 23.3% labor induction rate in 2012.

Oxytocic Pharmaceuticals Market: Drivers and Restraints

Increasing number of preterm births and rising labor induction rates are the primary factors responsible for the growth of global oxytocic pharmaceuticals market. Moreover, ascending cases of pregnancy related complications in developing countries, expanding use of oxytocic drugs in animals etc. are some other factors fueling the growth of global market for oxytocic pharmaceuticals. However, side effects and risks related to oxytocic drugs can be the only restraint for the growth of global oxytocic pharmaceuticals market.

Request Free Report Sample@ http://www.futuremarketinsights.com/reports/sample/rep-gb-1445

Oxytocic Pharmaceuticals Market: Segmentation

The global oxytocic market is classified on the basis of product type, source of origin, end use and geography.

Based on product type, the global oxytocic market has been segmented as follows:

Intravenous Infusion/Injection

Intramuscular Injection

Based on source of origin, the global oxytocic market has been segmented as follows:

Synthetic Oxytocin Derivative

Natural Oxytocin (animal pituitary extracts)

Based on end use, the global oxytocic market is segmented as follows:

Hospitals

Maternity Clinics

Request For TOC@ http://www.futuremarketinsights.com/toc/rep-gb-1445

Oxytocic Pharmaceuticals Market: Overview

Numerous oxytocic product offerings from various companies including the brands such as Evatocin, Pitogin, Octocin, Syntocinon, Tiacinon, Cytotec, Duratocin and Pitocin are competing to capture the market share in the global market for oxytocic pharmaceutical markets. Synthetic oxytocin derivatives segment is expected to contribute maximum share owing to easy availability of products. Hospital end user segment is anticipated to hold foremost share due to requirement of advanced healthcare infrastructure.

Oxytocic Pharmaceuticals Market: Region-wise Outlook

Geographically, the global oxytocic pharmaceuticals market is classified into regions namely, North America, Latin America, Western Europe, Eastern Europe, Asia-Pacific, Japan, Middle East and Africa. North America is expected to dominate the global market for oxytocic pharmaceuticals market owing to high rate for induced labor. Europe is anticipated to rank second in global oxytocic market due to increase in oxytocin administration with rising number of elective caesareans. As per NHS data, induction rate in England has increased from 22.1% in 2012 to 25.0% in 2014. Increasing number of cases for C-sections in countries such as India, China is expected to fuel the growth of oxytocic pharmaceutical market in Asia Pacific region.

Browse All Syndicated Market Research Reports@ http://www.futuremarketinsights.com/reports

Oxytocic Pharmaceuticals Market: Key Players

The global oxytocic pharmaceuticals market is dominated by Fresenius Kabi AG, LBS Labs, Biofutura Pharma SpA, APP Pharmaceuticals, LLC, JHP Pharmaceuticals, LLC, Baxter Healthcare Corporation, Pfizer Inc., Ferring B.V., Par Pharmaceutical, Inc. and others.